• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Recent advancements in pharmacological strategies to modulate energy balance for combating obesity.调节能量平衡以对抗肥胖的药理学策略的最新进展。
RSC Med Chem. 2023 Jun 14;14(8):1429-1445. doi: 10.1039/d3md00107e. eCollection 2023 Aug 16.
2
Chronic l-menthol-induced browning of white adipose tissue hypothesis: A putative therapeutic regime for combating obesity and improving metabolic health.慢性L-薄荷醇诱导白色脂肪组织褐变假说:一种对抗肥胖和改善代谢健康的推定治疗方案。
Med Hypotheses. 2016 Aug;93:21-6. doi: 10.1016/j.mehy.2016.05.006. Epub 2016 May 11.
3
Implications of nonshivering thermogenesis for energy balance regulation in humans.非颤抖性产热对人体能量平衡调节的意义。
Am J Physiol Regul Integr Comp Physiol. 2011 Aug;301(2):R285-96. doi: 10.1152/ajpregu.00652.2010. Epub 2011 Apr 13.
4
Translational Pharmacology and Physiology of Brown Adipose Tissue in Human Disease and Treatment.棕色脂肪组织在人类疾病与治疗中的转化药理学与生理学
Handb Exp Pharmacol. 2019;251:381-424. doi: 10.1007/164_2018_184.
5
Many Ways to Rome: Exercise, Cold Exposure and Diet-Do They All Affect BAT Activation and WAT Browning in the Same Manner?通往罗马的道路有千万条:运动、冷暴露和饮食——它们是否以相同的方式影响 BAT 的激活和 WAT 的棕色化?
Int J Mol Sci. 2022 Apr 26;23(9):4759. doi: 10.3390/ijms23094759.
6
Mitochondrial biogenesis: pharmacological approaches.线粒体生物合成:药理学方法。
Curr Pharm Des. 2014;20(35):5507-9. doi: 10.2174/138161282035140911142118.
7
Opportunities and challenges in the therapeutic activation of human energy expenditure and thermogenesis to manage obesity.治疗性激活人体能量消耗和产热以治疗肥胖的机遇与挑战。
J Biol Chem. 2020 Feb 14;295(7):1926-1942. doi: 10.1074/jbc.REV119.007363. Epub 2019 Dec 30.
8
The effect of weight management interventions that include a diet component on weight-related outcomes in pregnant and postpartum women: a systematic review protocol.包含饮食成分的体重管理干预措施对孕妇和产后女性体重相关结局的影响:一项系统评价方案
JBI Database System Rev Implement Rep. 2015 Jan;13(1):88-98. doi: 10.11124/jbisrir-2015-1812.
9
Challenging energy balance - during sensitivity to food reward and modulatory factors implying a risk for overweight - during body weight management including dietary restraint and medium-high protein diets.具有挑战性的能量平衡——在对食物奖励和调节因素敏感期间,这意味着存在超重风险——在体重管理期间,包括节食和中高蛋白饮食。
Physiol Behav. 2020 Jul 1;221:112879. doi: 10.1016/j.physbeh.2020.112879. Epub 2020 Mar 19.
10
Energy balance, physical activity, and cancer risk.能量平衡、身体活动与癌症风险。
Methods Mol Biol. 2009;472:57-88. doi: 10.1007/978-1-60327-492-0_3.

引用本文的文献

1
Natural bioactive compounds and their mechanisms of action in the management of obesity: a narrative review.天然生物活性化合物及其在肥胖管理中的作用机制:一项叙述性综述
Front Nutr. 2025 Jun 26;12:1614947. doi: 10.3389/fnut.2025.1614947. eCollection 2025.
2
The interplay of gut microbiota, obesity, and depression: insights and interventions.肠道微生物群、肥胖和抑郁的相互作用:见解和干预措施。
Cell Mol Life Sci. 2024 Oct 30;81(1):443. doi: 10.1007/s00018-024-05476-w.

本文引用的文献

1
BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.BI 456906:一种新型 GCGR/GLP-1R 双重激动剂的发现和临床前药理学研究,具有强大的抗肥胖疗效。
Mol Metab. 2022 Dec;66:101633. doi: 10.1016/j.molmet.2022.101633. Epub 2022 Nov 7.
2
Setmelanotide: A Novel Targeted Treatment for Monogenic Obesity.Setmelanotide:一种用于单基因肥胖的新型靶向治疗药物。
J Pharm Technol. 2022 Dec;38(6):368-373. doi: 10.1177/87551225221116010. Epub 2022 Aug 30.
3
Avian adjustments to cold and non-shivering thermogenesis: whats, wheres and hows.禽类对寒冷和非颤抖性产热的适应:什么、哪里和如何。
Biol Rev Camb Philos Soc. 2022 Dec;97(6):2106-2126. doi: 10.1111/brv.12885. Epub 2022 Jul 28.
4
Molecular mechanisms of topiramate and its clinical value in epilepsy.托吡酯的分子机制及其在癫痫中的临床价值。
Seizure. 2022 May;98:51-56. doi: 10.1016/j.seizure.2022.03.024. Epub 2022 Apr 4.
5
Semaglutide for weight loss and cardiometabolic risk reduction in overweight/obesity.司美格鲁肽用于超重/肥胖患者的体重减轻和改善心血管代谢风险
Curr Opin Cardiol. 2022 Jul 1;37(4):350-355. doi: 10.1097/HCO.0000000000000955. Epub 2022 Feb 16.
6
Ca leak through ryanodine receptor 1 regulates thermogenesis in resting skeletal muscle.钙通过兰尼碱受体 1 漏出使静止骨骼肌产热。
Proc Natl Acad Sci U S A. 2022 Jan 25;119(4). doi: 10.1073/pnas.2119203119.
7
Ancient Metagenomic Studies: Considerations for the Wider Scientific Community.古代宏基因组学研究:面向更广泛科学界的考量
mSystems. 2021 Dec 21;6(6):e0131521. doi: 10.1128/msystems.01315-21.
8
Amylin as a Future Obesity Treatment.胰淀素作为未来肥胖症的治疗手段。
J Obes Metab Syndr. 2021 Dec 30;30(4):320-325. doi: 10.7570/jomes21071.
9
Pharmacotherapy of obesity in complex diseases.复杂疾病中的肥胖症药物治疗。
Clin Obes. 2022 Feb;12(1):e12497. doi: 10.1111/cob.12497. Epub 2021 Dec 9.
10
Semaglutide for the Treatment of Type 2 Diabetes Mellitus.司美格鲁肽用于治疗2型糖尿病
J Pharm Technol. 2018 Dec;34(6):281-289. doi: 10.1177/8755122518790925. Epub 2018 Jul 30.

调节能量平衡以对抗肥胖的药理学策略的最新进展。

Recent advancements in pharmacological strategies to modulate energy balance for combating obesity.

作者信息

Pati Benudhara, Sendh Satyabrata, Sahu Bijayashree, Pani Sunil, Jena Nivedita, Bal Naresh Chandra

机构信息

School of Biotechnology, KIIT University Bhubaneswar Odisha 751024 India

Institute of Life Science, DBT ILS Bioincubator Bhubaneswar Odisha 751021-India.

出版信息

RSC Med Chem. 2023 Jun 14;14(8):1429-1445. doi: 10.1039/d3md00107e. eCollection 2023 Aug 16.

DOI:10.1039/d3md00107e
PMID:37593583
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10429841/
Abstract

The prevalence of obesity along with its related metabolic diseases has increased globally in recent decades. Obesity originates from a heterogeneous physiological state, which is further complicated by the influence of factors such as genetic, behavioural, and environmental. Lifestyle interventions including exercise and diet have limited success, necessitating the development of pharmacological approaches. Mechanistically, strategies target either reducing energy intake or increasing consumption through metabolism boosting. Current drugs lower energy intake inducing satiety or inhibiting substrate absorption, while targeting mitochondria or cytosolic energy sensors has shown limited success due to toxicity. Nonshivering thermogenesis (NST) has provided hope for activating these processes selectively without significant side effects. The internet-based marketing of plant-based formulations for enhancing metabolism has surged. This review compiles scientific articles, magazines, newspapers, and online resources on anti-obesity drug development. Combination therapy of metabolic boosters and established anti-obesity compounds appears to be a promising future approach that requires further research.

摘要

近几十年来,肥胖及其相关代谢疾病在全球范围内的患病率有所上升。肥胖源于一种异质性的生理状态,遗传、行为和环境等因素的影响使其进一步复杂化。包括运动和饮食在内的生活方式干预取得的成功有限,因此有必要开发药物治疗方法。从机制上讲,策略要么是减少能量摄入,要么是通过促进新陈代谢来增加能量消耗。目前的药物通过诱导饱腹感或抑制底物吸收来降低能量摄入,而针对线粒体或胞质能量传感器的方法由于毒性问题成效有限。非寒战产热(NST)为选择性激活这些过程且无明显副作用带来了希望。基于互联网的促进新陈代谢的植物性制剂营销激增。本综述汇编了有关抗肥胖药物研发的科学文章、杂志、报纸和在线资源。代谢增强剂与已有的抗肥胖化合物联合治疗似乎是一种有前景的未来方法,需要进一步研究。